Common Stock, Shares, Outstanding of Allogene Therapeutics, Inc. from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Summary
Allogene Therapeutics, Inc. quarterly Common Stock, Shares, Outstanding in shares history and change rate from 31 Dec 2017 to 31 Dec 2025.
  • Allogene Therapeutics, Inc. Common Stock, Shares, Outstanding for the quarter ending 31 Dec 2025 was 229,413,523, a 8.1% increase year-over-year.
Source SEC data
View on sec.gov
Common Stock, Shares, Outstanding, Quarterly (shares)
Common Stock, Shares, Outstanding, YoY Quarterly Change (%)

Allogene Therapeutics, Inc. Quarterly Common Stock, Shares, Outstanding (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 229,413,523 +17,202,926 +8.1% 31 Dec 2025 10-K 12 Mar 2026 2025 FY
Q3 2025 223,163,672 +13,663,535 +6.5% 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 220,133,876 +11,084,391 +5.3% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 218,598,262 +48,145,295 +28% 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 212,210,597 +43,568,359 +26% 31 Dec 2024 10-K 12 Mar 2026 2025 FY
Q3 2024 209,500,137 +41,324,916 +25% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 209,049,485 +41,915,821 +25% 30 Jun 2024 10-Q 07 Aug 2024 2024 Q2
Q1 2024 170,452,967 +24,712,634 +17% 31 Mar 2024 10-Q 13 May 2024 2024 Q1
Q4 2023 168,642,238 +24,203,934 +17% 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 168,175,221 +24,143,633 +17% 30 Sep 2023 10-K 14 Mar 2024 2023 FY
Q2 2023 167,133,664 +23,410,493 +16% 30 Jun 2023 10-K 14 Mar 2024 2023 FY
Q1 2023 145,740,333 +2,170,431 +1.5% 31 Mar 2023 10-K 14 Mar 2024 2023 FY
Q4 2022 144,438,304 +1,815,239 +1.3% 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 144,031,588 +1,591,759 +1.1% 30 Sep 2022 10-K 14 Mar 2024 2023 FY
Q2 2022 143,723,171 +1,602,440 +1.1% 30 Jun 2022 10-K 14 Mar 2024 2023 FY
Q1 2022 143,569,902 +2,099,827 +1.5% 31 Mar 2022 10-K 14 Mar 2024 2023 FY
Q4 2021 142,623,065 +2,148,760 +1.5% 31 Dec 2021 10-K/A 14 Mar 2024 2022 FY
Q3 2021 142,439,829 +2,683,990 +1.9% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 142,120,731 +2,887,281 +2.1% 30 Jun 2021 10-Q 04 Aug 2021 2021 Q2
Q1 2021 141,470,075 +16,207,538 +13% 31 Mar 2021 10-Q 05 May 2021 2021 Q1
Q4 2020 140,474,305 +16,206,947 +13% 31 Dec 2020 10-K 23 Feb 2022 2021 FY
Q3 2020 139,755,839 +17,860,360 +15% 30 Sep 2020 10-Q 04 Nov 2020 2020 Q3
Q2 2020 139,233,450 +17,602,172 +14% 30 Jun 2020 10-Q 05 Aug 2020 2020 Q2
Q1 2020 125,262,537 +3,735,217 +3.1% 31 Mar 2020 10-Q 06 May 2020 2020 Q1
Q4 2019 124,267,358 +2,784,687 +2.3% 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 121,895,479 +90,624,906 +290% 30 Sep 2019 10-Q 05 Nov 2019 2019 Q3
Q2 2019 121,631,278 30 Jun 2019 10-Q 07 Aug 2019 2019 Q2
Q1 2019 121,527,320 31 Mar 2019 10-Q 07 May 2019 2019 Q1
Q4 2018 121,482,671 +95,232,678 +363% 31 Dec 2018 10-K 27 Feb 2020 2019 FY
Q3 2018 31,270,573 30 Sep 2018 10-Q 21 Nov 2018 2018 Q3
Q4 2017 26,249,993 31 Dec 2017 10-K 08 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.